Brentuximab Vedotin

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma.

Nivolumab plus chemotherapy significantly extended PFS for children and adults with newly diagnosed advanced Hodgkin lymphoma compared with standard of care, according to results of a randomized phase 3 trial.

The addition of brentuximab vedotin to lenalidomide and rituximab extended OS among patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

In this video, Joshua Brody, MD, discussed the results of the SWOG S1826 trial of nivolumab vs. brentuximab vedotin in advanced-stage classic Hodgkin lymphoma, which were presented at ASCO Annual Meeting.

CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.

NEW ORLEANS — Induction with brentuximab vedotin plus AVD chemotherapy followed by nivolumab consolidation exhibited encouraging activity among previously untreated patients with limited-stage non-bulky Hodgkin lymphoma, according to study results.

The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

The FDA approved brentuximab vedotin in combination with chemotherapy for treatment of certain children with Hodgkin lymphoma, according to the agent’s manufacturer.